J
Janet Ford
Researcher at Texas Medical Center
Publications - 13
Citations - 458
Janet Ford is an academic researcher from Texas Medical Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 2 publications receiving 436 citations. Previous affiliations of Janet Ford include Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients.
Joseph Jankovic,Janet Ford +1 more
TL;DR: Tetrabenazine, lithium, and trihexyphenidyl were most useful for the treatment of oromandibular dystonia, and clonazepam was useful in some patients with blepharospasm.
Journal ArticleDOI
Progressive supranuclear palsy: Clinical features and response to treatment in 16 patients
TL;DR: Dopamine agonists such as bromocriptine and pergolide may be useful in some patients with PSP and anticholinergic drugs failed to benefit any of the 5 patients treated, while presynaptic dopaminergic drugs were beneficial in only 5 of 22 patient trials.
Journal ArticleDOI
Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER).
Anna Ambrosini,Emad Estemalik,Julio Pascual,Mallikarjuna Rettiganti,Chad Stroud,Kathleen Day,Janet Ford +6 more
TL;DR: It is demonstrated that galcanezumab has the potential to reduce acute headache medication use and overuse and HCRU in patients with prior migraine preventive treatment failures.
Journal ArticleDOI
Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials
Joshua Tobin,Janet Ford,Antje Tockhorn-Heidenreich,Russell M Nichols,Wenyu Ye,Rohit Bhandari,Xiaojuan Mi,Karan Sharma,Richard B. Lipton +8 more
TL;DR: GMB treatment resulted in annual indirect cost savings in patients with EM, CM, and with previous failure of 2-4 migraine preventive medication categories, with similar observations in the sensitivity analyses.
Journal ArticleDOI
Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN)
Joshua Tobin,Shivang Joshi,Janet Ford,Russell M Nichols,Shonda A. Foster,Dustin D. Ruff,Holland C. Detke,Sheena K. Aurora +7 more
TL;DR: Treatment with galcanezumab resulted in significant reductions in headache medication overuse and migraine headache days requiring acute medication use, with notable reductions in migraine-specific HCRU.